Successful use of laboratory monitoring to facilitate an invasive procedure for a patient treated with dabigatran
| Autor: | Sara Zochert, Michael P. Gulseth, Mackenzie Byron, Marioara Gavozdea-Barna, Thaddaus Hellwig |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Time Factors medicine.drug_class Blood Loss Surgical Pharmacy 030204 cardiovascular system & hematology Thrombin time Antithrombins Dabigatran Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Atrial Fibrillation Medicine Humans 030212 general & internal medicine Pharmacology Prothrombin time Aged 80 and over medicine.diagnostic_test business.industry Health Policy Anticoagulant Atrial fibrillation medicine.disease Surgery Femoral Neck Fractures Withholding Treatment Female Blood Coagulation Tests Hemiarthroplasty business Ecarin clotting time Biomarkers medicine.drug Partial thromboplastin time |
| Zdroj: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(7) |
| ISSN: | 1535-2900 |
| Popis: | Purpose A case in which novel and traditional laboratory markers were successfully used to determine surgical intervention timing in an elderly patient receiving dabigatran for atrial fibrillation is reported. Summary An 86-year-old woman who was taking dabigatran for atrial fibrillation suffered a right femoral neck fracture requiring surgical intervention. Dabigatran was withheld once the patient was admitted to the hospital, and the pharmacy inpatient anticoagulation management team was consulted for guidance on determining appropriate scheduling of surgical intervention with regard to the time since her most recent dabigatran dose to minimize bleeding complications. The team recommended delaying surgery, as dabigatran clearance would likely take 3–5 days and an ecarin chromogenic assay (ECA) dabigatran value of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|